<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03970343</url>
  </required_header>
  <id_info>
    <org_study_id>CA_CP_307</org_study_id>
    <nct_id>NCT03970343</nct_id>
  </id_info>
  <brief_title>Post Approval Study (PAS) of the OPTIMIZER Smart and CCM Therapy</brief_title>
  <acronym>PAS</acronym>
  <official_title>A Prospective, Multi-center, Non-randomized, Single Arm Open Label Study of 620 Subjects Receiving the OPTIMIZER Smart With CCM Therapy as Standard of Care</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Impulse Dynamics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Impulse Dynamics</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The OPTIMIZER Smart Post-Approval Study is a prospective, multi-center, non-randomized,
      single arm open label study of 620 subjects receiving an OPTIMIZER implant as standard of
      care. Patients to be included will have NYHA functional class III symptoms and a left
      ventricular ejection fraction of 25-45%
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The Impulse Dynamics OPTIMIZER Smart Pre-Market Application (PMA) clinical data confirmed
      that CCM therapy delivered with the Optimizer meaningfully improved health outcomes in
      patients with NYHA class III heart failure symptoms and left ventricular ejection fraction of
      25-45%. CCM has shown significant improvements in quality of life measures, with an average
      improvement of &gt;11 points in MLHWFQ incremental to the improvement of a randomized control
      group with no device. Six minute hall walk and functional class also showed improvements in
      the PMA data. The post-approval study (PAS) protocol has been designed to evaluate long term
      safety and efficacy of the OPTIMIZER Smart in a real-world setting.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 21, 2020</start_date>
  <completion_date type="Anticipated">December 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2023</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>3 Years</target_duration>
  <primary_outcome>
    <measure>Incidence of procedure and device-related complications</measure>
    <time_frame>1 year</time_frame>
    <description>Demonstrate, in the post-approval setting, that the OPTIMIZER Smart is safe to use, by assessing the rate of procedure related complications (30 days) and device related complications (1-year)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>All-cause mortality</measure>
    <time_frame>3 years</time_frame>
    <description>Observed mortality will be compared to the predicted mortality according to the Seattle Heart Failure Model (SHFM) at 1 year and 3 years post-implant</description>
  </primary_outcome>
  <enrollment type="Anticipated">620</enrollment>
  <condition>Heart Failure</condition>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>OPTIMIZER Smart</intervention_name>
    <description>Eligible subjects will receive the OPTIMIZER Smart, which is comprised of three major components:
Programmable Optimizer Smart Implantable Pulse Generator (IPG)
OMNI Smart Programmer
Optimizer Smart Charger
Two commercially available intravascular leads complete the system.</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Participants will represent a patient population with stable, systolic left ventricular
        dysfunction and moderate symptomatic heart failure despite guideline-directed medical
        therapy.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patient or legally authorized representative provides written authorization and/or
             consent per institution and geographical requirements

          2. Male or non-pregnant female, aged 18 or older

          3. Left ventricular ejection fraction of 25-45% (inclusive)

          4. NYHA Class III heart failure symptoms

          5. Stated willingness to comply with all study procedures and availability for the
             duration of the study

          6. Patient has been treated with guideline-directed heart failure therapies with stable
             doses for at least 1 month

        Exclusion Criteria:

          1. Infiltrative or inflammatory cardiomyopathy (e.g. amyloid, hemochromatosis,
             myocarditis, hypertrophic cardiomyopathy, Fabry disease, cardiac tumor)

          2. Primary heart failure due to uncorrected mitral valve disease, or mitral valve repair
             or clip within 3 months of enrollment.

          3. IV inotropes, hemofiltration, or any form of positive inotropic support within 30 days
             before enrollment, including continuous IV inotrope therapy

          4. Myocardial infarction within 3 months of enrollment.

          5. Undergone a CABG procedure within 3 months or a PTCA procedure within 30 days of
             enrollment.

          6. Persistent (lasting more than 7 days) or permanent lasting more than 1 year) atrial
             fibrillation or atrial flutter or cardioverted within 30 days of enrollment.

          7. Prior heart transplant or ventricular assist device

          8. Mechanical tricuspid valve

          9. PR interval greater than 375ms

         10. Receiving cardiac resynchronization therapy (CRT) or has a Class I indication for CRT
             implantation according to the ACCF/AHA/HRS guidelines for device-based therapy

         11. Currently on dialysis

         12. Currently undergoing treatment for cancer

         13. Participating in another cardiac investigational study at the same time

         14. Patient is in a vulnerable population (such as significant mental disability,
             prisoner) that in the judgement of the PI impedes ability to provide informed consent.

         15. Other criteria that precludes Optimizer implantation and/or CCM therapy, as determined
             by Investigator
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rami Kahwash, MD</last_name>
    <role>Study Director</role>
    <affiliation>The Ohio State University Wexner Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Raul Weiss, MD</last_name>
    <role>Study Director</role>
    <affiliation>The Ohio State University Wexner Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Angela Stagg</last_name>
    <phone>845-359-2389</phone>
    <phone_ext>206</phone_ext>
    <email>angelas@impulse-dynamics.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Southwest Cardiovascular Associates</name>
      <address>
        <city>Mesa</city>
        <state>Arizona</state>
        <zip>85206</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Megan Bellamy</last_name>
      <phone>480-945-4343</phone>
      <phone_ext>210</phone_ext>
      <email>mbellamy@swcva.com</email>
    </contact>
    <investigator>
      <last_name>Charles Jost, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Naples Heart Rhythm Specialists</name>
      <address>
        <city>Naples</city>
        <state>Florida</state>
        <zip>34119</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jori Richardson</last_name>
      <phone>239-330-5670</phone>
      <email>jrichardson@naplesheartrhythm.com</email>
    </contact>
    <investigator>
      <last_name>Kenneth Plunkitt, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Advent Orlando</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32792</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Damaris Valesquez</last_name>
      <phone>407-630-9997</phone>
      <email>dvalesquez@rpna.net</email>
    </contact>
    <investigator>
      <last_name>Usman Siddiqui</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Baptist Lexington</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40503</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Kristie Schneider</last_name>
      <phone>859-260-6429</phone>
      <email>kschneid@bhsi.com</email>
    </contact>
    <investigator>
      <last_name>Gery Tomassoni, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Our Lady of Lourdes</name>
      <address>
        <city>Camden</city>
        <state>New Jersey</state>
        <zip>08103</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Marissa Brown</last_name>
      <phone>856-673-1346</phone>
      <email>MBrown3@virtua.org</email>
    </contact>
    <investigator>
      <last_name>Heath Saltzman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rutgers Medical School</name>
      <address>
        <city>Newark</city>
        <state>New Jersey</state>
        <zip>07719</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maria Scibilia</last_name>
      <phone>973-972-6806</phone>
      <email>maria.scibilia@rutgers.edu</email>
    </contact>
    <investigator>
      <last_name>Emad Aziz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Valley Hospital</name>
      <address>
        <city>Ridgewood</city>
        <state>New Jersey</state>
        <zip>07450</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Nancy Bowden</last_name>
      <phone>201-389-0193</phone>
      <email>nbowden@valleyhealth.com</email>
    </contact>
    <investigator>
      <last_name>Suneet Mittal, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ohio State University</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jany Kim</last_name>
      <phone>614-292-4826</phone>
      <email>january.kim@osumc.edu</email>
    </contact>
    <investigator>
      <last_name>Toshimasa Okabe, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Regional Cardiac Arrythmia Inc.</name>
      <address>
        <city>Steubenville</city>
        <state>Ohio</state>
        <zip>43952</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Alison Maltony</last_name>
      <phone>740-792-4220</phone>
      <email>alison.maltony@hotmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Emily Anderson</last_name>
      <phone>740-792-4220</phone>
      <email>emilyanderson802@gmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Maninder Bedi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mercy Health - St. Vincent Medical Center</name>
      <address>
        <city>Toledo</city>
        <state>Ohio</state>
        <zip>43608</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Michelle Hickam</last_name>
      <phone>419-251-4919</phone>
      <email>michelle_hickam@mercy.com</email>
    </contact>
    <investigator>
      <last_name>Ameer Kabour, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Abington Memorial Hospital</name>
      <address>
        <city>Abington</city>
        <state>Pennsylvania</state>
        <zip>19001</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Matthew Dreese</last_name>
      <phone>215-481-4193</phone>
      <email>matthew.dreese@jefferson.edu</email>
    </contact>
    <investigator>
      <last_name>Richard Borge, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Bryn Mawr Hospital</name>
      <address>
        <city>Bryn Mawr</city>
        <state>Pennsylvania</state>
        <zip>19010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Anne Henry</last_name>
      <phone>610-525-1202</phone>
      <email>ahenry@bmmsa.com</email>
    </contact>
    <investigator>
      <last_name>Sheetal Chandhok, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Penn State Hershey Medical Center</name>
      <address>
        <city>Hershey</city>
        <state>Pennsylvania</state>
        <zip>17033</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Kevin Gardner</last_name>
      <phone>717-531-6508</phone>
      <email>kgardner@pennstatehealth.edu</email>
    </contact>
    <investigator>
      <last_name>Howard Eisen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital of the University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nicole Escobar</last_name>
      <phone>215-662-2683</phone>
      <email>nicole.escobar@Pennmedicine.upenn.edu</email>
    </contact>
    <investigator>
      <last_name>Edo Birati, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Penn Presybyterian Medical Center</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Katie Shoemaker</last_name>
      <phone>856-630-1547</phone>
      <email>katie.shoemaker@pennmedicine.upenn.edu</email>
    </contact>
    <investigator>
      <last_name>Benjamin D'Souza, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Temple University Hospital</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19140</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Carrie Farmer</last_name>
      <phone>215-707-0756</phone>
      <email>cfarmer1@temple.edu</email>
    </contact>
    <investigator>
      <last_name>Isaac Whitman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Reading Hospital</name>
      <address>
        <city>Reading</city>
        <state>Pennsylvania</state>
        <zip>19611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Julie Sheidy</last_name>
      <phone>484-628-4317</phone>
      <email>Julie.sheidy@towerhealth.org</email>
    </contact>
    <investigator>
      <last_name>Jared Green, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Marshall Cardiology</name>
      <address>
        <city>Huntington</city>
        <state>West Virginia</state>
        <zip>25701</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Melissa Marcum</last_name>
      <phone>304-691-8560</phone>
      <email>mmarcum@marshall.edu</email>
    </contact>
    <investigator>
      <last_name>Carlos Rueda, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Aurora Research Institute</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Brad Dumville</last_name>
      <phone>414-649-7132</phone>
      <email>bradley.dumville@aah.org</email>
    </contact>
    <contact_backup>
      <last_name>Rebecca Dahme</last_name>
      <phone>262-249-5432</phone>
      <email>Rebecca.Dahme@aah.org</email>
    </contact_backup>
    <investigator>
      <last_name>Imran Niazi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>May 23, 2019</study_first_submitted>
  <study_first_submitted_qc>May 30, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 31, 2019</study_first_posted>
  <last_update_submitted>June 25, 2020</last_update_submitted>
  <last_update_submitted_qc>June 25, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 29, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>OPTIMIZER</keyword>
  <keyword>Heart Failure</keyword>
  <keyword>CCM</keyword>
  <keyword>Post-Approval Study</keyword>
  <keyword>NYHA class III</keyword>
  <keyword>FIX-HF-5C</keyword>
  <keyword>Chronic heart failure</keyword>
  <keyword>Ejection fraction between 25 and 45</keyword>
  <keyword>cardiac contractility modulation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

